JP2022514254A5 - - Google Patents

Info

Publication number
JP2022514254A5
JP2022514254A5 JP2021534201A JP2021534201A JP2022514254A5 JP 2022514254 A5 JP2022514254 A5 JP 2022514254A5 JP 2021534201 A JP2021534201 A JP 2021534201A JP 2021534201 A JP2021534201 A JP 2021534201A JP 2022514254 A5 JP2022514254 A5 JP 2022514254A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514254A (ja
JP7618553B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/060957 external-priority patent/WO2020128861A1/en
Publication of JP2022514254A publication Critical patent/JP2022514254A/ja
Publication of JP2022514254A5 publication Critical patent/JP2022514254A5/ja
Application granted granted Critical
Publication of JP7618553B2 publication Critical patent/JP7618553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534201A 2018-12-18 2019-12-17 ラパマイシン誘導体 Active JP7618553B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862781242P 2018-12-18 2018-12-18
US62/781,242 2018-12-18
PCT/IB2019/060957 WO2020128861A1 (en) 2018-12-18 2019-12-17 Rapamycin derivatives

Publications (3)

Publication Number Publication Date
JP2022514254A JP2022514254A (ja) 2022-02-10
JP2022514254A5 true JP2022514254A5 (cg-RX-API-DMAC7.html) 2022-12-26
JP7618553B2 JP7618553B2 (ja) 2025-01-21

Family

ID=69165426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534201A Active JP7618553B2 (ja) 2018-12-18 2019-12-17 ラパマイシン誘導体

Country Status (20)

Country Link
US (1) US12281125B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898637B1 (cg-RX-API-DMAC7.html)
JP (1) JP7618553B2 (cg-RX-API-DMAC7.html)
KR (1) KR102978080B1 (cg-RX-API-DMAC7.html)
CN (1) CN113260619B (cg-RX-API-DMAC7.html)
AU (1) AU2019409366B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011325A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122922A1 (cg-RX-API-DMAC7.html)
DK (1) DK3898637T3 (cg-RX-API-DMAC7.html)
ES (1) ES3014225T3 (cg-RX-API-DMAC7.html)
FI (1) FI3898637T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250197T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070859T2 (cg-RX-API-DMAC7.html)
LT (1) LT3898637T (cg-RX-API-DMAC7.html)
MX (1) MX2021007247A (cg-RX-API-DMAC7.html)
PL (1) PL3898637T3 (cg-RX-API-DMAC7.html)
PT (1) PT3898637T (cg-RX-API-DMAC7.html)
RS (1) RS66527B1 (cg-RX-API-DMAC7.html)
SI (1) SI3898637T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020128861A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
KR20260115158A (ko) 2019-03-26 2026-07-23 노파르티스 아게 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
WO2024211738A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69637641D1 (de) 1995-06-07 2008-09-25 Ariad Gene Therapeutics Inc Auf rapamycin basierende regulation biologischer vorgänge
KR19990022651A (ko) * 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
DE69624921T2 (de) 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CA2257803C (en) 1996-07-12 2008-12-02 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
WO1999036553A2 (en) 1998-01-15 1999-07-22 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
GB0601406D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
US20090023768A1 (en) 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
WO2008022256A2 (en) 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2011133636A1 (en) 2010-04-20 2011-10-27 Cedars-Sinai Medical Center COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
EP2670758B1 (en) 2011-02-04 2022-09-28 Synthon BV Process for making trisubstituted silyloxyethyl triflates
CN103391780B (zh) 2011-02-16 2015-08-19 诺瓦提斯公司 用于治疗神经变性疾病的治疗剂的组合物
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EP3109250A1 (en) 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CA3061907A1 (en) 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
KR20260115158A (ko) 2019-03-26 2026-07-23 노파르티스 아게 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2022527270A5 (cg-RX-API-DMAC7.html)
JP2020535134A5 (cg-RX-API-DMAC7.html)
HRP20250197T1 (hr) Derivati rapamicina
JP2020502047A5 (cg-RX-API-DMAC7.html)
JP6964096B2 (ja) 3−オキソ−2,6−ジフェニル−2,3−ジヒドロピリダジン−4−カルボキサミド類
HRP20240199T1 (hr) Derivati rapamicina
JP2021523113A5 (cg-RX-API-DMAC7.html)
US10414732B2 (en) Polymorphic compounds and uses thereof
JP2020189879A5 (cg-RX-API-DMAC7.html)
JP2014525426A5 (cg-RX-API-DMAC7.html)
JP2017505784A5 (cg-RX-API-DMAC7.html)
JP2007512283A5 (cg-RX-API-DMAC7.html)
JP2014525427A5 (cg-RX-API-DMAC7.html)
HRP20240633T1 (hr) Izotiazolidin 1,1-dioksid i 1,4-butan sulton derivati rapamicina i njihova uporaba
JP2014512406A5 (cg-RX-API-DMAC7.html)
RU2020121150A (ru) Твердые формы ингибитора калликреина плазмы и его солей
JP2019504899A5 (cg-RX-API-DMAC7.html)
JP6407955B2 (ja) クマリン誘導体、ならびに過剰増殖疾患を治療する際の使用方法
JP2021528488A5 (cg-RX-API-DMAC7.html)
JP2018535963A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
JP2021105002A5 (cg-RX-API-DMAC7.html)
JP2022501429A5 (cg-RX-API-DMAC7.html)
JP2012502980A5 (cg-RX-API-DMAC7.html)
JP2015508092A5 (cg-RX-API-DMAC7.html)